Skip to content

Author

Lixia Chen

We have 4 of 51 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Identification of CD40 as the target of artemisinin via targeted degradomics for ulcerative colitis.

Current drugs for ulcerative colitis often face challenges such as significant side effects, high costs, and tendency to induce drug resistance. Repurposing existing drugs is a promising approach that builds on their known safety and efficacy profiles. Artemisinin (Art), a first-line antimalarial agent, shows anti-infl...

Zhi-Qi Zhang, Hao-Ze Song, Yi-Xing Li et al. · 0 citations
Open access Sep 2026

The molecular basis of ADP-ribose pyrophosphorylation by a phage PRPS-like enzyme in NAD+ reconstitution

Abstract Depletion of cellular NAD+ is an increasingly recognized bacterial antiphage strategy, and many phages counter this pressure by rebuilding NAD+ from its cleavage products. In the NARP1 pathway, Adps converts ADP-ribose (ADPR) and ATP into ADPR-PP, the immediate substrate for Namat-dependent NAD+ synthesis, but...

Meng-Xi Liu, Jing-Bo Ma, Qing-Qing Zhang et al. · 0 citations
Review Sep 2026

Comprehensive insights into Astragalus membranaceus polysaccharides: Extraction, structural characteristics, bioactivities, and applications: A review.

This review comprehensively evaluates APS extraction, structural characterization, biological activities, and application, with particular emphasis on the evidence linking preparation-dependent structural variation to biological responses.

Jing Cheng, Qian-Hui Liu, Rui Zhu et al. · 0 citations
Aug 2026

Discovery of DCAF16-based PROTACs as SHP2 degraders.

The design and synthesis of SHP2 PROTACs that recruit the DCAF16 E3 ligase for targeted SHP2 degradation are reported that support the potential of SHP2-targeted protein degradation as an alternative strategy to enzymatic inhibition and provide a promising starting point for the further development of SHP2 degraders.

X. Pang, Yuxin Gan, Qing-Yuan Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.